

ViroGates issues warrants to Management

ViroGates A/S (Nasdaq First North Growth Market Denmark: VIRO), who delivers blood test systems, primarily for acute care departments in hospitals, today announces that the Board of Directors has granted warrants to Management in accordance with ViroGates' "General guidelines for incentive pay" approved at the annual general meeting on 24 May 2018 as well as section 4.2.5 of the Nasdaq First North Growth Market Rulebook.

The purpose of the long-term share-based incentive programme is to align the interests of participants and ViroGates' shareholders and thereby support the company's long-term objective to deliver sustainable value creation for the shareholders.

The grant comprises a total of 119,324 warrants to Management, and the main terms and conditions for the warrant program are:

- Warrants have been granted free of charge and vest four years after grant.
- Upon vesting, each vested warrant may be exercised over a five-year period following the publication of a quarterly financial report.
- Each vested warrant entitles the participant to subscribe for one share in ViroGates at an exercise price of DKK 35 per share corresponding to the closing price of the ViroGates' shares prior to grant.
- The exercise price of the warrants is inflated by 12% annually.
- If the warrants are not exercised within the five-year period after vesting, they will lapse without compensation.
- The total number of warrants, which may be exercised under this grant, corresponds to 3.9% of ViroGates' total outstanding shares.

The announcement can be found at <https://www.virogates.com/investor/announcements>

For further information contact:

CEO Jakob Knudsen

Tel. (+45) 2113 1336, Email: jk@virogates.com

ViroGates A/S

CVR-nr. 25734033

Blokken 45, DK-340 Birkerød

www.virogates.com

Certified Advisor

Västra Hamnen Corporate Finance

Per Lönn

Tel. (+46) 40 200 250, Email: per.lonn@vhcorp.se

About ViroGates

ViroGates is an international medtech company developing and marketing prognostics products to the healthcare sector. Based on more than 600 clinical trials and studies, ViroGates' suPARnostic® product range supports hospital professionals in making clinical decisions on hospitalization or discharge of acute care patients as well as detecting and assessing the severity of cardiovascular diseases, type 2 diabetes, cancer, etc. suPARnostic® TurbiLatex is available on Roche Diagnostics' cobas instruments and ViroGates works with partners to develop solutions for other platforms. Headquartered in Denmark, ViroGates' sales force covers the Nordics, Germany, Spain and France, while distributors serve other markets. www.virogates.com